Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

8.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Emerging Trends in Cancer Drug Discovery-From Drugging the "Undruggable" to Overcoming Resistance.

Cancer discovery·2021
Same author

A gene expression signature associated with ''K-Ras addiction'' reveals regulators of EMT and tumor cell survival.

Cancer cell·2021
Same author

Thinking Differently about Cancer Treatment Regimens.

Cancer discovery·2021
Same author

Unprovoked Stabilization and Nuclear Accumulation of the Naked Mole-Rat p53 Protein.

Scientific reports·2020
Same author

Targeting microtubules sensitizes drug resistant lung cancer cells to lysosomal pathway inhibitors.

Theranostics·2020
Same author

A Single-Step, High-Dose Selection Scheme Reveals Distinct Mechanisms of Acquired Resistance to Oncogenic Kinase Inhibition in Cancer Cells.

Cancer research·2019

Related Experiment Video

Updated: Apr 17, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K

Predicting response to HER2 kinase inhibition.

Jeff Settleman1

  • 1Discovery Oncology, Genentech, Inc., South San Francisco, CA.

Oncotarget
|February 7, 2015
PubMed
Summary

Human Epidermal growth factor Receptor 2 (HER2) and Human Epidermal growth factor Receptor 3 (HER3) work together to control cancer cell growth. Their combined action influences how sensitive cancer cells are to the investigational drug TAK-285.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The study comments on the cooperative roles of Human Epidermal growth factor Receptor 2 (HER2) and Human Epidermal growth factor Receptor 3 (HER3) in cancer progression.
  • It highlights the significance of these receptors in regulating cancer cell proliferation and survival.

Discussion:

  • The commentary emphasizes that the combined signaling of HER2 and HER3 is crucial for driving cancer cell growth.
  • It suggests that targeting both HER2 and HER3 may be a viable strategy for cancer therapy.

Key Insights:

  • Co-expression and co-activation of HER2 and HER3 are critical determinants of cancer cell growth.
  • Sensitivity to the investigational EGFR/HER2 kinase inhibitor TAK-285 is directly linked to the cooperative function of HER2 and HER3.

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.4K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.7K

Related Experiment Videos

Last Updated: Apr 17, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K
Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.4K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.7K

Outlook:

  • Further research into the intricate interplay between HER2 and HER3 signaling pathways is warranted.
  • The findings support the development of targeted therapies, such as TAK-285, that inhibit the HER2/HER3 axis for improved cancer treatment outcomes.